Trim 35-40% at $432, tighten stop to $418-420; retain 60-65% core on quality floor
The Aug 27 prior lesson is dispositive: all three conditions for 35-45% trim (lower-high formation, 20%+ extension above 200 SMA, negative forward EPS revisions) are confirmed. The Neutral Analyst's 35-40% at current levels is the most executable middle ground — it captures the asymmetric setup without requiring the rally the bearish divergence argues against (price has drifted lower three consecutive sessions: $440.34 → $436.99 → $432.42) or overreacting like the Conservative Analyst's 50-60% on a 0.41-beta mega-cap with intact FCF and 6.3x interest coverage. The 0.41 defensive beta, 2.29% dividend yield, and deleveraging trajectory ($234B market cap, net debt down 11% YoY) justify retaining 60-65% core rather than full exit; selling into confirmed regime conditions with structural uptrend above the 50 SMA ($386) would replicate the August 11 over-correction error. The Research Manager's $415 stop is rejected as providing insufficient buffer against the $9.96 ATR; the volatility-adjusted $418-420 honors the noise regime while defining structural invalidation.
| Position | Action |
|---|---|
| At current levels ($432) with confirmed bearish divergence, lower-high formation, 20%+ extension above 200 SMA, and negative forward EPS revisions | Trim 35-40% of long position |
| Retain core exposure as quality floor (2.29% dividend, 6.3x interest coverage, $3.49B quarterly FCF, intact deleveraging trajectory) | Retain 60-65% as core position |
| Re-engagement Tier 1: $400-410 with RSI reset below 60 AND forward EPS revisions stabilizing | Add 25-33% of original intended size |
| Re-engagement Tier 2: $385-395 (50 SMA + Fibonacci cluster) on confirmed basing with bullish reversal candle | Add higher-conviction reload position |
AMGN is undergoing a structural transformation from mature pharma to growth-biotech turnaround, with accelerating fundamentals (Q2 2026 revenue +9.5% YoY, 72% gross margins, strong FCF), real deleveraging (net debt down 11% YoY, cash up 74%), and multiple Phase 3 pipeline catalysts (Tezspire EoE success this week) that aren't priced into the 17.7x forward P/E.
| Indicator | Value | Signal |
|---|---|---|
| Close | $432.42 | neutral |
| 10 EMA | $432.25 | neutral |
| 50 SMA | $385.94 | bullish |
| 200 SMA | $351.47 | bullish |
| RSI (14) | 64.60 | neutral |
| MACD | +16.20 | neutral |
| MACD Signal | +16.48 | neutral |
| MACD Histogram | -0.28 | bearish |
| Bollinger Upper Band | $457.04 | neutral |
| Bollinger Middle Band | $419.77 | neutral |
| Bollinger Lower Band | $382.51 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Then: Add 25-33% of original intended size
Patent cliff fears are five years stale — the pipeline is already generating revenue and Tezspire EoE is blockbuster-scale
↩ rebuts: “Patent Cliff on Enbrel, Repatha Biosimilars — Structural Decline”
· concedes: Rate environment partially compresses pipeline NPV calculations; MariTide is a binary risk with potential to truncate upside
AMGN's valuation already prices in pipeline success that hasn't materialized, with multiple technical bearish divergences, a leveraged balance sheet at refinancing risk, and a single large binary catalyst (MariTide) creating asymmetric downside risk that does not justify adding capital at 52-week highs.
EV: Downside: -11% to $385 (50 SMA); -19% to $351 (200 SMA); -25-30% to $300-$320 on MariTide failure + macro shock. Upside: +6-11% to $460-$480 if everything goes right. · concedes: AMGN has a real business with real cash flow; The dividend and defensive characteristics justify owning the stock; AMGN is a hold, not a sell, for existing shareholders who want the yield and defensive exposure
→ vs conservative: Full exit requires calling an absolute top at 432 with zero structural breakdown; the 50 SMA at 385.94 hasn't been tested and 200 SMA at 351.47 is still rising
→ vs conservative: A full exit means being forced to chase back in if the breakout above 445 holds, making it a weaker trade than trimming into strength
→ vs neutral: Textbook bearish divergence at second-highest level in 60-day lookback; optimal exit window is BEFORE the 50 SMA breaks, not after — by the time price closes below 386, trim price will be much lower in the 360s
→ vs neutral: The dividend, deleveraging, and margin expansion are already in the price after the 16.5% absolute outperformance; these are holding costs, not catalysts
→ vs neutral: Marginal buyer relies on dividend ETF flows and pipeline news, but the next major event is MariTide — a coin flip against GLP-1 incumbents with multi-year commercial head start
| neutral |
| ATR (14) | $9.96 | neutral |
Support: 419.77 · 385.94 · 382.51 · 351.47 | Resistance: 437 · 445 · 457.04
AMGN exhibits a structurally bullish setup with price well above both the 50 SMA ($385.94, +12%) and 200 SMA ($351.47, +23%), and both averages in a rising stack confirming a sustained medium-term advance. However, the short-term picture shows early exhaustion signals: the MACD histogram turned negative (-0.28) after the MACD line peaked at 18.06 on 08-25 and has been declining, while RSI pulled back from an overbought 79.8 peak on 08-19 to 64.60, indicating mild bearish divergence vs. price. Price is retreating from the upper Bollinger band ($457.04) toward the middle band ($419.77), and ATR has expanded to $9.96, reflecting heightened volatility. The path of least resistance remains up, but a decisive break above $437 with volume or a pullback to the 50 SMA zone ($378-$385) is needed to provide the next clear trade entry.
Market Cap
$233.78 B
P/E (TTM)
26.89x
Forward P/E
17.72x
PEG Ratio
2.32
Price / Book
20.00x
EPS (TTM)
$16.08
Forward EPS
$24.40
Dividend Yield
2.29%
Beta
0.413
Revenue 2022
$26,323M
Revenue 2025
$36,751M
Revenue Growth 2022-2025
+39.6%
Net Income 2024
$4,090M
Net Income 2025
$7,711M
Net Income Growth 2024-2025
+88%
Diluted EPS 2025
$14.23
Diluted EPS Q2 2026
$4.37
Gross Margin (TTM)
71.9%
Operating Margin (TTM)
35.5%
EBITDA Margin (TTM)
45.3%
Profit Margin (TTM)
22.95%
EBITDA (TTM)
$17.27 B
Return on Assets (ROA)
8.67%
Return on Invested Capital (ROIC)
~25%
Return on Equity (ROE)
91.47%
Free Cash Flow (TTM)
$8.65 B
FCF Q2 2026
$3.49 B
CapEx (run-rate)
~$2.5 B/year
Total Debt
$57.30 B
Net Debt
$43.32 B
Cash & Equivalents
$13.99 B
Stockholders' Equity
$11.69 B
Current Ratio
1.37
Debt/Equity
6.31x
Debt Service Coverage (EBITDA/Interest)
6.3x
52-Week High
$447.03
52-Week Low
$269.77
50-Day MA
$386.07
200-Day MA
$355.39
Diluted Shares Q2 2026
544 M
Annual Dividends
~$5.3 B / ~$10/share
Dividend Quarterly
~$2.50
Strengths
Concerns
Amgen Inc. (AMGN) is a mega-cap biotechnology company with a $233.78B market capitalization that demonstrated strong fundamental recovery in 2025, with net income jumping 88% to $7.71B and diluted EPS nearly doubling to $14.23. The company maintains robust profitability metrics (45.3% EBITDA margin, 35.5% operating margin) and generates substantial free cash flow (TTM ~$8.65B), while executing disciplined deleveraging that reduced net debt 11% to $43.32B. Despite concerns around $57.3B total debt load, pipeline binary risks around MariTide obesity assets, and patent cliffs on legacy biologics, the stock trades at a reasonable forward P/E of 17.72x with 52% implied EPS growth to $24.40, supported by defensive characteristics (beta 0.413) and an above-average 2.29% dividend yield.
Macro: Fed path remains the dominant macro driver with Polymarket pricing only 1% September 2026 cut probability and 10% December, consistent with 'higher for longer' narrative flagged in press via 'Warsh concerns.' US recession probability at 8% ($1.7M volume) maintains soft-landing thesis, supportive for drug volume demand. Gold settling lower on inflation persistence concerns corroborates rising term premium story. Standard FRED macro series (CPI, core PCE, fed funds rate, 10y Treasury, unemployment, VIX) unavailable in this run — qualitative direction inferred from news flow, not fabricated data. Sector rotation favoring dividend ETFs (SCHD +$679M inflows, +2.39%) provides incremental bid for income-quality mega pharma like AMGN. Peer signals from Eli Lilly confirming net drug price compression is an industry-wide theme.